Medshine Discovery Inc.

Merck Sharp + Dohme Corp.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Harbin Zhenbao Pharmaceutical Co., Ltd.

Chinese Academy of Sciences

Cstone Pharmaceuticals

Fujian Akeylink Biotechnology Co., Ltd.

Genfleet Therapeutics (shanghai) Inc.

Fujian Cosunter Pharmaceutical Co., Ltd.

Shandong New Time Pharmaceutical Co., Ltd.

Suzhou Genhouse Pharmaceutical Co., Ltd

China Resources Pharmaceutical Holdings Company Limited

Lihong Hu

Charles Z Ding

Shuhui Chen

Jian Li

Guoping Hu

Jianyu Lu

Yong Wang

Xile Liu

Zhaobing Xu

Thomas H Graham

John S Wai

Sherman Tim Waddell

Tie-Lin Wang

Xuanjia Peng

Weidong Li

Xiongbin Xu

John M Sanders

John D Schreier

Paul J Coleman

Izzat Tiedje Raheem

Lingyun Wu

Kun Peng Wang

Tao Yu

Mark W Embrey

Wen Jiang

Andrew William Stamford

Lili Zhang

John A McCauley

Hong Ding

Xiquan Zhang

Hualiang Jiang

Lu Zhang

Peng Liu

Lianyun Zhao

Rui Zhao

Yonglian Zhang

Jun Zhao

Timothy John Hartingh

Xu Zeng

Thomas G Steele

Abbas M Walji

John T Sisko

Jingya Li

Huijun He

Jiaqiang Dong

Shenyi Shi

Haiwen Wan

Yingchun Liu

Lun Lu

Yaxian Cai

Hailong Yang

Shiqi Han

Xiangyu Fu

Kun Wang

Gang Li

Jiaqiang Cai

Lele Zhao

Ning Zhao

Wensheng Liu

Bin Shi

Ronald Dale Ferguson, Ii

Lifang Wu

Ting Yao

Wei Pan

Zongbin Li

Xu Shen

Zhibo Zhang

Qingqing Lu

Liguang Lou

Xiu Jiang

Yong Shao

Hankun Zhang

Jinping Li

Yaling Zhou

Wenqian Yang

Zhijuan Chen

Shuwen Duan

Xingxun Zhu

Bingjie Ren

Jia Li

Zhigang Chi

Christine Ng Di Marco

Jiming Ye

Christina Ng Di Marco

Zhe Cheng

Shaohua Zhao

Mengxia Zhou

Zijian Yao

Xiangjun Li

Disclosed are a group of 5-(4-pyridyloxy)pyrazole compounds serving as a TGF-βR1 kinase inhibitor, and applications of same in preparing a TGF-βR1 kinase inhibitor medicament. Specifically disclosed are the compounds as represented by formula (I), a pharmaceutically acceptable salt or an isomer thereof.

5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor

Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Estrogen receptor antagonist

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor

Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor

A pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and a preparation method therefor and application thereof. The pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof is simple to synthesize, easy to prepare, rich in raw materials for synthesis, and has an inhibitory effect on a plurality of tyrosine kinases, especially has higher selective inhibitory activity against KDR (VEGFR2), and FLT3 and its mutants, and can avoid toxic side effects caused by inhibiting KDR.

Pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and preparation method therefor and application thereof

Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Compounds containing benzosultam

Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof. (I)

3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors

Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor

Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor. 

Uracil compound as c-MET/AXL inhibitor

Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof. 

Pyrimidine compound acting on EGFR and ERBB2

Disclosed are a crystal form of a c-MET inhibitor and a salt form thereof and a preparation method therefor. Specifically involved are the compound as shown in formula (I), and a salt form and a crystal form thereof, and also included is the use of the crystal form and the salt form in the preparation of medicines for treating cancers. 

Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor

Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof. 

Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer. 

SMAC mimetics used as IAP inhibitors and use thereof

A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof. 

Salt serving as AKT inhibitor and crystal thereof

Growing community of inventors

Shanghai, China

Lihong Hu